Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Lixte Biotechnology Holdings, Inc. announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam, and Oncode Institute, Utrecht to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
[Lixte Biotechnology Holdings, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

HNF Collaborates with Rarebase on a Drug Discovery Platform to Develop Treatments for Charcot-Marie-Tooth (CMT)

The Hereditary Neuropathy Foundation (HNF), in partnership with Rarebase, is leading the charge in the first-ever research initiative to tackle multiple types of CMT in one project, with a primary goal to test candidate drugs in patient-derived cellular models, specifically; iPSC-derived neurons.
[The Hereditary Neuropathy Foundation]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S reported that the US FDA has accepted a Supplemental New Drug Application for the treatment of schizophrenia in adolescents with Rexulti® and has granted Otsuka and Lundbeck Priority Review.
[Otsuka Pharmaceutical Co., Ltd. (BusinessWire, Inc.)]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Trellis Rx Furthers Commitment to Advancing the Specialty Pharmacy Practice and Patient Outcomes with Integration of Scipher Medicine® PrismRA® Precision-Medicine Technology into Clinical Pathways

Researchers announced the integration of PrismRA® into its clinical pathway for patients living with rheumatoid arthritis. Scipher Medicine, the manufacturer of PrismRA, is a precision immunology company helping providers determine the most effective therapy for their patients.
[Trellis Rx (BusinessWire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase IIIb Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Arcturus Therapeutics Holdings, Inc. announced that the Vietnam Ministry of Health has approved initiation of the Phase IIIb part of the placebo-controlled, observer-blind Phase I/II/III clinical trial of ARCT-154 self-replicating RNA vaccine targeting the SARS-CoV-2 delta variant and other variants of concern.
[Arcturus Therapeutics Holdings, Inc.]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the US FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Merck and Ridgeback Biotherapeutics announced that Merck has submitted an Emergency Use Authorization application to the FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization.
[Merck (BusinessWire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Chinchilla Supplier Loses License over Animal Welfare Violations

Moulton Chinchilla Ranch, the main US source of the animals for research, had a years-long history of disturbing findings in USDA inspections.
[The Scientist LLC]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, announced positive results of a mechanistic study of TTP399 in patients with type 1 diabetes.
[vTv Therapeutics, Inc.]
[zotpress userid=” items=’ARAWWK92′ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China

Hansoh Pharmaceutical Group Co, Ltd and OliX Pharmaceuticals, Inc. announced a licensing and collaboration agreement to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.
[Hansoh Pharmaceutical Group Co, Ltd (GlobeNewswire, Inc.)]
[zotpress userid=” items=’ARAWWK92′ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Cynata Signs a Landmark New Strategic Partnership Agreement with Fujifilm

Cynata Therapeutics Limited has entered into a new strategic partnership with Fujifilm Corporation which includes detailed and agreed core terms for Fujifilm to provide clinical & commercial manufacturing services for, as well as supply of, the vompany’s Cymerus™ therapeutic MSC products.
[Kalkin Media]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Gates Biomanufacturing Facility Announces Strategic Manufacturing Partnership with Cell Therapy Pioneer, Nkarta

The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic Natural Killer cells. As part of this collaboration, GBF will continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
[Gates Biomanufacturing Facility]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share